Will open source biotechnology benefit the bottom billion?

Add to your list(s) Download to your calendar using vCal

• Jenny Molloy (OpenPlant and Synthetic Biology Strategic Research Initiative) & Lalitha Sundaram (Department of Pathology)
• Wednesday 11 November 2015, 12:00-14:00
• Seminar Room SG2, Alison Richard Building.

If you have a question about this talk, please contact Centre For Global Equality .

Speaker: Jenny Molloy (OpenPlant and Synthetic Biology Strategic Research Initiative) Respondent: Lalitha Sundaram (Department of Pathology)

These are some of the issues Jenny will address: Openness has developed as a paradigm and movement in fields like government and science over the last decade, building on successes of open source models in software. Biotechnology is historically a sector where proprietary technologies and multinational corporations have dominated, but there is a growing interest in opening up the tools and technologies necessary to develop biotechnological solutions in agriculture, health, bioremediation and more. This is particularly true in the emerging field of synthetic biology, which takes an engineering approach to biological innovation and has already delivered yeast producing anti-malarial compounds, bacterial arsenic biosensors and sterile mosquitoes. What does openness mean in synthetic biology and is it achievable from the lab to the field? Will open really enable equal access and democratisation of biotechnology to solve local problems or will the same power structures be maintained?

This talk is part of the Science non-Fiction & the Bottom Billion: Evolving Frameworks for a fairer Future series.

This talk is included in these lists:

• Science non-Fiction & the Bottom Billion: Evolving Frameworks for a fairer Future
• Seminar Room SG2, Alison Richard Building

Note that ex-directory lists are not shown.